Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNOPHYLATE vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of bronchial asthma,Chronic bronchitis,Emphysema,Acute asthmatic exacerbations (off-label)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2 and CYP3A4 isoenzymes.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40-60% bound, primarily to albumin.
65% bound to albumin
Vd is approximately 0.3-0.7 L/kg, indicating distribution into total body water. Higher Vd in hyperthyroid states, lower in obesity.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral: 80-100% for immediate-release; 90-100% for extended-release. Rectal: 80-90%.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
GFR 30-50 m L/min: 50% of normal dose; GFR <30 m L/min: 25% of normal dose or extend interval to 12-24 hours.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh A: no adjustment; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated or 25% of normal dose with monitoring.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
10-15 mg/kg/dose orally every 6-8 hours; maximum 60 mg/kg/day.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Start at 300 mg every 8 hours; titrate cautiously due to increased risk of accumulation and adverse effects.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None.
No FDA black box warning.
Narrow therapeutic index; monitor serum levels. Dosage should be individualized. Avoid excessive caffeine intake.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to xanthine derivatives, active peptic ulcer disease, and seizure disorders.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) and charcoal-grilled foods, which can reduce theophylline absorption. High-fat meals may increase absorption; take consistently with meals.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal nephrotoxicity. Late third trimester: Risk of premature closure of ductus arteriosus and persistent pulmonary hypertension of the newborn.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Contraindicated during breastfeeding due to high M/P ratio of 3.5, leading to significant infant exposure with potential for adverse effects including renal impairment and gastrointestinal bleeding.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No dose adjustment required; pharmacokinetics unchanged in pregnancy. However, avoid use after 28 weeks gestation due to fetal renal effects.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
SYNOPHYLATE (theophylline) has a narrow therapeutic index; serum levels should be monitored to maintain 5-15 mcg/m L. Use with caution in patients with heart failure, liver disease, or COPD, as clearance is reduced. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and carbamazepine decrease levels. Avoid in seizure disorders.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without medical advice, as it affects drug levels.,Inform all healthcare providers you are taking this medication, especially if starting new drugs.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNOPHYLATE vs AEROLATE, answered by our medical review team.
SYNOPHYLATE is a Bronchodilator that works by SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNOPHYLATE and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNOPHYLATE is: 400-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNOPHYLATE and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNOPHYLATE is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal n. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.